cas 65193-87-5|| where to buy 2-Cyanoethyl 3-oxobutanoate

Produktname:2-Cyanoethyl 3-oxobutanoate

IUPAC Name:2-cyanoethyl 3-oxobutanoate

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM184421-100g	in stock	ƩȋƏ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 65193-87-5 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:65193-87-5; Molekulare Formel:C7H9NO3; Schmelzpunkt:-; SMILES-Code:CC(CC(OCCC#N)=O)=O; Dichte:

: Katalognummer:CM184421; Molekulargewicht:155.15; Siedepunkt:288.196°C at 760 mmHg; Mdl-Nr.:MFCD24687999; Lagerung:Store in freezer, under -20°C.

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Finerenone; Bayer announced that FINEARTS-HF met its primary endpoint, achieving a statistically significant reduction of the composite of cardiovascular death and total (first and recurrent) heart failure (HF) events, defined as hospitalizations for HF or urgent HF visits. The randomized, double-blind, placebo-controlled, parallel-group, multi-center phase III cardiovascular outcomes study evaluated the efficacy and safety of KERENDIA® (finerenone) for investigational new use in patients with HF with a LVEF≥40% (left ventricular ejection fraction). Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that was approved to reduce the risk of cardiovascular death, non-fatal myocardial infarction, hospitalization for heart failure, sustained eGFR decline, and end-stage kidney disease in adult patients with CKD associated with T2D.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.